Anagrelide - CAS 68475-42-3
Catalog number:
68475-42-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C10H7Cl2N3O
Molecular Weight:
256.09
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Anagrelide is a phosphodiesterase inhibitor with antiplatelet activity with IC50 value of 36 nM for inhibition of phosphodiesterase 3. It inhibits the maturation of megakaryocytes into platelets, reducing both megakaryocyte hyperproliferation and differentiation. It is antithrombocythemic used for the treatment of overproduction of blood platelets. It is a synthetic quinazoline derivative and is used as is a platelet-reducing agent. It reduces platelet production through a decrease in megakaryocyte maturation. It inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia. It was developed by Shire and has been listed.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Ivory powder
Synonyms:
6,7-Dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one;6-Chloro-1,2,3,5-tetrahydro iMidazo [2,1-b]quinazolin-2-one;Agrelin;Agrylin;Xagrid;Shire;Thromboreductin
Solubility:
Soluble in DMSO, not in water
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Anagrelide is used for the treatment of overproduction of blood platelets. It is a drug used for the treatment of essential thrombocytosis or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
Quality Standard:
In-house standard
Quantity:
Kilograms to Tons
Boiling Point:
376.5°C at 760 mmHg
Melting Point:
280 °C
Density:
1.77±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
OTBXOEAOVRKTNQ-UHFFFAOYSA-N
InChI:
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
Canonical SMILES:
C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31
Current Developer:
Anagrelide was developed by Shire and has been listed.
1.Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S1, Tefferi A1. Blood Cancer J. 2015 Nov 13;5:e366. doi: 10.1038/bcj.2015.95.
Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in PV and ET include disease transformation into myelofibrosis (MF) or acute myeloid leukemia (AML). The range of reported frequencies for post-PV MF were 4.9-6% at 10 years and 6-14% at 15 years and for post-ET MF were 0.8-4.9% at 10 years and 4-11% at 15 years. The corresponding figures for post-PV AML were 2.3-14.4% at 10 years and 5.5-18.7% at 15 years and for post-ET AML were 0.7-3% at 10 years and 2.1-5.3% at 15 years. Risk factors cited for post-PV MF include advanced age, leukocytosis, reticulin fibrosis, splenomegaly and JAK2V617F allele burden and for post-ET MF include advanced age, leukocytosis, anemia, reticulin fibrosis, absence of JAK2V617F, use of anagrelide and presence of ASXL1 mutation.
2.Influence of platelet and white blood cell counts on major thrombosis - Analysis from a patient registry in Essential Thrombocythemia.
Buxhofer-Ausch V1,2, Steurer M3, Sormann S4, Schloegl E5, Schimetta W6, Gisslinger B1, Ruckser R7, Gastl G3, Gisslinger H1. Eur J Haematol. 2016 Apr 1. doi: 10.1111/ejh.12759. [Epub ahead of print]
OBJECTIVES: Although guidelines recommend normalization of platelet counts as an appropriate endpoint for treatment in high-risk essential thrombocythemia (ET), retrospective studies could not prove a correlation of diagnostic platelet counts with an increased thrombotic rate. There is, however, an increasing evidence that leukocytosis is an important risk factor for arterial thrombosis in myeloproliferative neoplasms.
3.Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D1, Mascarenhas J. Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.
PURPOSE OF REVIEW: Management of polycythemia vera and essential thrombocythemia requires understanding of the key concepts regarding diagnosis, risk stratification, and management.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


Indimilast
(CAS: 1038825-85-2)

Indimilast is a phosphodiesterase IV inhibitor. It modulates lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-mon...

CAS 317-34-0 Aminophylline

Aminophylline
(CAS: 317-34-0)

Aminophylline is a competitive nonselective phosphodiesterase inhibitor with an IC50 of 0.12 mM and also a nonselective adenosine receptor antagonist.

CAS 171599-83-0 Sildenafil Citrate

Sildenafil Citrate
(CAS: 171599-83-0)

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...

CAS 81840-15-5 Vesnarinone

Vesnarinone
(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

CAS 77671-31-9 Enoximone

Enoximone
(CAS: 77671-31-9)

Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure.

PDE10-IN-1 is a potent PDE10-IN-1 inhibi
(CAS: 1516896-09-5)

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor which can be used to treat CNS disorders and metabolic disorders.

CAS 1082744-20-4 PF-04447943

PF-04447943
(CAS: 1082744-20-4)

PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor (Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high se...

ITI214
(CAS: 1642303-38-5)

ITI214 is a highly selective PDE1 inhibitor (Ki = 58 pM) at picomolar concentration without disrupting other PDE family members and a panel of enzymes, receptor...

CAS 58579-51-4 Anagrelide Hydrochloride

Anagrelide Hydrochloride
(CAS: 58579-51-4)

Anagrelide is a drug used for the treatment of essential thrombocytosis,or overproduction of blood platelets. It also has been used in the treatment of chronic ...

CAS 1082743-70-1 PDE-9 inhibitor

PDE-9 inhibitor
(CAS: 1082743-70-1)

PDE-9 inhibitor is useful for neurodegenerative diseases.

CAS 141184-34-1 Filaminast

Filaminast
(CAS: 141184-34-1)

Filaminast is a Type 4 cyclic nucleotide phosphodiesterase inhibitor. It is an analog of rolipram which served as a prototype molecule for several development e...

CAS 3321-06-0 Denaverine hydrochloride

Denaverine hydrochloride
(CAS: 3321-06-0)

Denaverine hydrochloride is a phosphodiesterase inhibitor.Denaverine hydrochloride is applied in relaxation and delatation of birth canal in animals and spasms ...

CAS 1013750-77-0 ML-030

ML-030
(CAS: 1013750-77-0)

ML-030, a triazolothiadiazine, is a potent PDE4 inhibitor in a cell-based cyclic nucleotide-gated cation channel biosensor assay (EC50 = 18.7 nM), with IC50 of ...

CAS 13460-98-5 Theodrenaline

Theodrenaline
(CAS: 13460-98-5)

Theodrenaline, also known as noradrenalinoethyltheophylline, is a cardiac stimulant with anti-hypotensive property together with cafedrine.

RPL-554
(CAS: 298680-25-8)

RPL 554 is a potent and selective PDE3/4 inhibitor for respiratory diseases, particularly in patients with asthma.

CAS 1229652-21-4 HA-130

HA-130
(CAS: 1229652-21-4)

HA-130, an effective autotaxin (ATX) inhibitor, has been found to restrain the cell migration related to ATX in in an A2058 melanoma cells. IC50: 28 nM.

CP 461
(CAS: 227619-96-7)

CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...

CAS 794568-92-6 BAY 73-6691

BAY 73-6691
(CAS: 794568-92-6)

BAY 73-6691 is a phosphodiesterase inhibitor selective for the PDE9A subtype under the development of Bayer. It selectively inhibits human PDE9 with IC50 value ...

CAS 106730-54-5 Olprinone

Olprinone
(CAS: 106730-54-5)

Olprinone(Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.

CAS 1238697-26-1 TAK-063

TAK-063
(CAS: 1238697-26-1)

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...

Chemical Structure

CAS 68475-42-3 Anagrelide

Quick Inquiry

Verification code

Featured Items